在完成I期临床试验的单剂量递增研究后，集团将会按照计划启动I期多剂量递增研究(“MAD研究”)，以进一步评估耐受性和疗效，加快推动LAE102的临床研发及商务进展。集团致力于将这种精准治疗带给那些需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。Lai Kay Pharmaceuticals-B (02105) rose more than 7% in the morning session, as of the time of publication, increased by 7.03% to HK$14.3, with a turnover of 30.551 million Hong Kong dollars.
According to the Wisdom Finance APP, Lai Kay Pharmaceuticals-B (02105) rose more than 7% in the morning session, as of the time of publication, increased by 7.03% to HK$14.3, with a turnover of 30.551 million Hong Kong dollars.
On the news front, Lai Kay Pharmaceuticals-B issued an announcement that the Phase I clinical trial of LAE102 is progressing smoothly. As of the date of this announcement, all subjects (64 subjects in total, 8 intravenous infusion and subcutaneous injection dose escalation cohorts) in the Phase I single-dose escalation study ('SAD study') have completed dosing. Early signs of target binding and expected biomarker changes, as well as good safety, have been observed. The Phase I clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of LAE102 injection in healthy adult subjects and overweight/obese subjects.
Following the completion of the Phase I single-dose escalation study, the group will proceed with the planned Phase I multiple-dose escalation study ('MAD study') to further evaluate tolerability and efficacy, accelerating the clinical research and commercial progress of LAE102. The group is committed to bringing this precision treatment to overweight and obese patients who need new treatment options to achieve high-quality weight control.
